{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:15:03Z","timestamp":1757618103085,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bulcan.2025.02.018","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T16:10:30Z","timestamp":1743955830000},"page":"961-968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and toxicity of the LMBA02 protocol for Burkitt lymphoma in Morocco"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-1084","authenticated-orcid":false,"given":"Sophia","family":"Berrada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Naim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Benayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Benmoussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Lamchahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdellah","family":"Madani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Qachouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.02.018_bib0110","first-page":"22","article-title":"Adult Burkitt lymphoma: advances in diagnosis and treatment","volume":"30","author":"Aldoss","year":"2008","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.bulcan.2025.02.018_bib0115","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s12185-010-0591-z","article-title":"Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: Experience of C\u00f4te d\u2019Ivoire","volume":"91","author":"Koffi","year":"2010","journal-title":"International journal of hematology"},{"year":"2017","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues vol","author":"Swerdlow","key":"10.1016\/j.bulcan.2025.02.018_bib0120"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0125","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0130","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.bulcan.2025.02.018_bib0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.2009-S2-30","article-title":"Expert opinions on positron emission tomography and computed tomography imaging in lymphoma","volume":"14","author":"Delbeke","year":"2009","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bulcan.2025.02.018_bib0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2018.07.013","article-title":"Burkitt lymphoma\u00a0\u2013\u00a0a rare but challenging lymphoma","volume":"31","author":"Casulo","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0145","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2141.2011.08771.x","article-title":"Diagnosis of Burkitt lymphoma using an algorithmic approach\u00a0\u2013\u00a0applicable in both resource-poor and resource-rich countries","volume":"154","author":"Naresh","year":"2011","journal-title":"Br J Haematol"},{"issue":"10036","key":"10.1016\/j.bulcan.2025.02.018_bib0150","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0155","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.ejca.2004.09.004","article-title":"Gender and age-related differences in Burkitt lymphoma\u00a0\u2013\u00a0epidemiological and clinical data from The Netherlands","volume":"40","author":"Boerma","year":"2004","journal-title":"Eur J Cancer"},{"issue":"10036","key":"10.1016\/j.bulcan.2025.02.018_bib0160","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0140-6736(16)00164-1","article-title":"Chemoimmunotherapy as a new standard of care for Burkitt leukaemia\/lymphoma","volume":"387","author":"Jabbour","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-017-3167-7","article-title":"Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens","volume":"97","author":"Oosten","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0170","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-Malternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0175","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0180","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis","volume":"8","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0185","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cncr.28264","article-title":"Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Castillo","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0190","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.16425","article-title":"Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients","volume":"189","author":"Jakobsen","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0200","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0205","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.bulcan.2025.02.018_bib0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","article-title":"Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the Center for International Blood and Marrow Transplant Research","volume":"19","author":"Maramattom","year":"2013","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125001420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125001420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:12:44Z","timestamp":1757175164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125001420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0007455125001420"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.02.018","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy and toxicity of the LMBA02 protocol for Burkitt lymphoma in Morocco","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}